Erschienen in:
10.12.2015 | Original Article
RETRACTED ARTICLE: Clinical significance and expression of the PRSS3 and Wiskott–Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancer
verfasst von:
Sima Azizmohammadi, Aghdas Safari, Mehri Seifoleslami, Rahman Ghaffarzadegan Rabati, Mohsen Mohammadi, Hamid Yahaghi, Susan Azizmohammadi
Erschienen in:
Tumor Biology
|
Ausgabe 5/2016
Einloggen, um Zugang zu erhalten
Abstract
In this study, we evaluate the clinical significance of the PRSS3 and Wiskott–Aldrich syndrome protein family verprolin-homologous protein 1 (WAVE1) in patients with epithelial ovarian cancer (EOC) by immunohistochemistry.
In current study, all adjacent non-cancerous tissues showed absent or low expression of PRSS3. The expression of PRSS3 was significantly increased in the EOCs than adjacent non-cancerous tissues. Moreover, the expression of WAVE1 was significantly observed in all EOC tissues when compared with normal tissues. Furthermore, WAVE1 expression was absent in 35 (89.74 %) adjacent non-cancerous tissues.
Our findings showed that high expression of PRSS3 was markedly linked to FIGO stage (P = 0.02), advanced grade (P = 0.017), and lymph node metastases (P = 0.001), but no relationship was determined with other clinicopathological parameters. Furthermore, high expression of WAVE1 was significantly correlated with FIGO stage (P = 0.001), grade of tumor (P = 0.011), and residual tumor size (P = 0.041), but no significant associations were found between WAVE1 expression and age, lymph node metastasis, and histological subtypes (all P > 0.05). In conclusion, our study showed that increased expression of PRSS3 and WAVE1 may be involved in development of EOC.